A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Withdrawn. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 3
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · SINGLE
- Evidence population
- Human clinical study registration
- Participants
- 0
- Population
- ALL · 50 Years
- Duration
- 2023-12-29 to 2026-01-30
- Intervention
- Ranibizumab; Aflibercept; Port Delivery System with ranibizumab (PDS)
- Comparator
- Aflibercept
- Outcomes measured
- Change from baseline in BCVA score at week 80 as assessed using the ETDRS visual acuity chart at a starting distance of…; Treatment burden as assessed by the treatment frequency up to Week 80 — From baseline up to 80 weeks; Proportion of subjects with BCVA score of 69 letters (approximate 20/40 Snellen equivalent) or better averaged over Wee…; Proportion of subjects with BCVA score of 38 letters (approximate 20/200 Snellen equivalent) or worse averaged over Wee…; Proportion of subjects who lose < 15, < 10, or < 5 letters in BCVA score from baseline averaged over Weeks 76 (or 78*)…; Change from baseline in center point thickness (CPT) at Week 80 — Baseline, Week 80; Change from baseline in center subfield thickness (CST), defined as the average thickness of the central 1 mm circle of…; Proportion of subjects randomized to PDS Q36W who do not undergo supplemental treatment with intravitreal ranibizumab 0…; Incidence and severity of ocular and systemic (non-ocular) adverse events — Baseline, Week 80; Incidence, severity, and duration of adverse events of special interest, including ocular adverse events of special int…; Incidence, severity, and duration of ocular adverse events of special interest during the postoperative period (≤ 37 da…; Incidence and severity of adverse device effects with PDS Q36W — Baseline, Week 80; Incidence, causality, severity, and duration of anticipated serious adverse device effects with PDS Q36W — Baseline, We…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.